Description
DUTABIOT V2 – latest generation hair mesotherapy
CONTACT US IF YOU ARE INTERESTED IN DISTRIBUTION OR IF YOU ARE A HAIR CLINIC.
Orders from POLAND – please contact the exclusive distributor at orders@dutabiot.com.pl
Orders from California – please contact Irvine Skin / OC med derm (exclusive distributors)
Mexico: please contact Overnia (exclusive distributors)
We are happy to bring you the new generation of this dutasteride mesotherapy product that is finally here to stop and reverse your androgenetic hair loss. Clinically backed (see below)
This new ultrafiltered, sterile formula contains dutasteride 0.02% and biotin in 10 ml and it does not cause the burning sensation at the injection site as the previous product (that had to be mixed with lidocaine to reduce the pain). It comes in an amber color light blocking multi-use rubber stopper vial.
Advantages over other formulas:
- ultrafiltered, aqueous solution, easy flow even with 30g needles
- pain free for the scalp, unlike more viscous solutions
- made in EU in a high quality GMP lab
- very competitive pricing
- added biotin for synergistic action
- literally no local inflammation compared to oily substances, good absorption
- fast shipping worldwide
Dutasteride mesotherapy is one of the very few solutions as of today that is really capable to regrow your hair and with the added biotin it contains the most important vitamin in the hair growth cycle.
Dutasteride is the only approved DHT-blocker substance that acts on both isomers of the 5-alpha reductase enzyme and it is effective in both genders. It has a lot higher potency than finasteride in blocking the 5-AR enzyme.
1 vial of 10 ml – about 2 ml is used per session, depending on the technique – the better the technique, less the spilling
EVALUATION OF THE EFFECT OF INJECTION OF DUTASTERIDE AS MESOTHERAPEUTIC TOOL IN TREATMENT OF ANDROGENETIC ALOPECIA IN MALES
Abstract
Introduction: Androgenetic alopecia (AGA) is hereditary and androgen dependent, progressive thinning of the scalp hair that follows a defined pattern.
Aim ot the work: is to evaluate the efficacy and safety of mesotherapy using dutasteride in treatment of androgenetic alopecia in males.
Materials and Methods: Ninety male patients were randomly assigned into three groups; group A containing 30 patients who received pure
dutasteride, group B of another 30 patients who received dutasteride containing solution and group C of the remaining 30 patients who
received saline. Each group was given nine mesotherapy sessions. Assessment was done using trichogram, independent observer assessment
of photographs and patients self assessment together with evaluation of possible systemic absorption using semenogram and serum
dihydrotestosterone (DHT).
Result: Statistical analysis of the thrichogram results, the effect on semenogram and the serum level of dihydrotestosterone.showed that
dutastride containing solution was the best.
Conclusion: Mesotherapy using dutasteride is a good option for treatment of male pattern hair loss; resulting in reduction or cessation of hair
loss and promotion of new hair growth.
Key words: methotherapy; dutastride; male; androgenetic alopecia; trichogram
Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation
Abstract
BACKGROUND:
Treatment of female pattern hair loss (FPHL) is frustrating for both patients and doctors. Mesotherapy is a novel treatment for hair fall and its efficacy in FPHL has not been evaluated.
OBJECTIVE:
Evaluation of the efficacy and safety of mesotherapy using dutasteride-containing preparation in treatment of FPHL.
METHODS:
This study included 126 female patients with FPHL. They were classified into two groups; group I (86 patients) injected with dutasteride-containing preparation and group II (40 control patients) injected with saline. Patients received 12 sessions and were evaluated at the 18th week by: photographic assessment, hair pull test, hair diameter and patient self-assessment. Ultrastructural evaluation was done for three patients.
RESULTS:
After mesotherapy with dutasteride-containing preparation, photographic improvement occurred in 62.8% of patients compared with 17.5% in control group (P < 0.05), mean number of epilated hairs was significantly decreased (P < 0.05), mean hair diameter was significantly increased (P < 0.05). Patient self-assessment showed statistically significant improvement compared with the controls (P < 0.05). There was a negative correlation between degree of improvement and duration of FPHL (P < 0.05). Side effects were minimal with no statistically significant difference between the two groups (P > 0.05). Ultrastructural examination of pretreated hairs revealed absent cuticle in one patient and focal destruction of the cuticle in the second patient, which reappeared in both after therapy.
CONCLUSION:
We concluded that mesotherapy with dutasteride-containing preparation was effective, tolerable and minimally invasive treatment modality in FPHL with better response for shorter duration of the disease.
RF-Mesotherapy With Dutasteride: A Future Alternative Treatment for Androgenetic Alopecia
Mesotherapy using dutasteride-containing preparation in treatment of female pattern hair loss: photographic, morphometric and ultrastructural evaluation
Abstract
Background: Treatment of female pattern hair loss (FPHL) is frustrating for both patients and doctors. Mesotherapy is a novel treatment for hair fall and its efficacy in FPHL has not been evaluated.
Objective: Evaluation of the efficacy and safety of mesotherapy using dutasteride-containing preparation in treatment of FPHL.
Methods: This study included 126 female patients with FPHL. They were classified into two groups; group I (86 patients) injected with dutasteride-containing preparation and group II (40 control patients) injected with saline. Patients received 12 sessions and were evaluated at the 18th week by: photographic assessment, hair pull test, hair diameter and patient self-assessment. Ultrastructural evaluation was done for three patients.
Results: After mesotherapy with dutasteride-containing preparation, photographic improvement occurred in 62.8% of patients compared with 17.5% in control group (P < 0.05), mean number of epilated hairs was significantly decreased (P < 0.05), mean hair diameter was significantly increased (P < 0.05). Patient self-assessment showed statistically significant improvement compared with the controls (P < 0.05). There was a negative correlation between degree of improvement and duration of FPHL (P < 0.05). Side effects were minimal with no statistically significant difference between the two groups (P > 0.05). Ultrastructural examination of pretreated hairs revealed absent cuticle in one patient and focal destruction of the cuticle in the second patient, which reappeared in both after therapy.
Conclusion: We concluded that mesotherapy with dutasteride-containing preparation was effective, tolerable and minimally invasive treatment modality in FPHL with better response for shorter duration of the disease.
Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice
Published online June 23, 2022
Background: 5-alpha inhibitors are an effective treatment for androgenetic alopecia. Mesotherapy with dutasteride has been proposed as an effective method to improve hair loss and reducing systemic absorption.
Objective: The main objective was to describe the safety profile of mesotherapy with dutasteride in real clinical practice in a large cohort of patients with androgenetic alopecia. A secondary aim was to describe the effectiveness of this treatment.
Methods and Materials: A multicentric retrospective study was designed. Patients treated with at least 6 months of follow-up were included in the study. Side effects and response to the treatment were analyzed.
Results: A total of 541 patients were included. The commonest approach during the first year was to perform the treatment every 3 months. Response to the mesotherapy in monotherapy could be assessed in 86 patients (15.9%) after one year. Most of them presented clinical improvement, being a marked improvement in 33 patients (38.4%). Pain was the most frequent side effect of the treatment (246 patients, 45.5%). No serious or sexual adverse events were detected.
Conclusion: Mesotherapy with dutasteride was effective in male and female hair loss in real clinical practice. Side effects related to the treatment were mild and self-limited. This therapy may be an effective option for select patients wishing to avoid oral treatment.
J Drugs Dermatol. 2022;21(7):742-747. doi:10.36849/JDD.6610
INTRODUCTION
Androgenetic alopecia (AGA) is the most frequent cause of hair loss in men and women. According to epidemiological studies, 80% of Caucasian men and 40-50% of women will develop AGA over the course of their lifetime.1 AGA is characterized by a decrease in hair density in androgenetic areas of the scalp due to a progressive miniaturization of the hair follicle. The etiopathogenesis is multifactorial and complex.2
Androgens play an important role. Their influence is especially relevant in men, and still controversial in women.3,4 Hair follicles in persons with androgenetic alopecia (AGA) are genetically susceptible to androgens. The activity of 5-alpha-reductase enzyme converts free testosterone into 5-α-dihydrotestosterone (5-α-DHT). 5-α-DHT binds to the androgen receptor in the dermal papilla of the hair follicle and activates the genes responsible for the gradual hair loss. After several hair cycles, the duration of anagen phase shortens and matrix size decreases, resulting in clinically evident miniaturized hairs.4 Peripheral antiandrogens, like the inhibitors of 5-alpha-reductase, have been proven to be effective in stopping this mechanism and also to revert hair thinning. Oral finasteride, which inhibits type II enzyme, is an FDA approved drug to treat AGA. Oral dutasteride inhibits both type I and II enzymes, and its use in AGA is considered off-label. The systemic use of both drugs has been attributed to side effects including sexual impotence, ejaculation disorders, and decrease of libido. Although clinical trials have not demonstrated a clear correlation between the use of these drugs and those side effects,5 they represent a primary concern for patients considering treatment.
In order to limit systemic absorption of 5-alpha-reductase inhibitors, their use as mesotherapy preparations has increased over the last several years. Mesotherapy technique involves microinjection of substances into the dermis or subcutaneous tissue for the treatment of various dermatological conditions, such as alopecia, cellulite, and wrinkles.6,7 Dutasteride-containing preparations might be an option to treat AGA in
Reviews
There are no reviews yet.